Cluster-randomized clinical trial examining the impact of platelet function testing on practice: The Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study

Circulation: Cardiovascular Interventions

Volumn 8, Issue 6, 2015, Pages

  Wang, Tracy Y ^a   Henry, Timothy D ^b   Effron, Mark B ^c   Honeycutt, Emily ^a   Hess, Connie N ^a   Zettler, Marjorie E ^c   Cohen, David J ^d   Baker, Brian A ^e   Berger, Peter B ^f   Anstrom, Kevin J ^a   Angiolillo, Dominick J ^g   Peterson, Eric D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Lilly USA   (United States)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^e DAIICHI SANKYO INC   (United States)

^f GEISINGER MEDICAL CENTER   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Percutaneous coronary intervention; physicians' treatment choice; platelet function testing

Indexed keywords

ADENOSINE DERIVATIVE; ADENOSINE DIPHOSPHATE RECEPTOR INHIBITOR; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CLUSTER ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; FEMALE; FUNCTION TEST; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE FUNCTION; TREATMENT PLANNING; AGED; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; LONGITUDINAL STUDY; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TREATMENT OUTCOME;

EID: 84937579502     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.001712     Document Type: Article

References (31)

1. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58:1945-1954. doi: 10.1016/j.jacc.2011.06.059.
2. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303:754-762. doi: 10.1001/jama.2010.181.
3. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516. doi: 10.1016/j.jacc.2006.11.044.
4. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261-2273. doi: 10.1016/j.jacc.2013.07.101.
5. Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, Rossi P, Ait-Mokhtar O, Jouve B, Collet F, Peyre JP, Wittenberg O, de Labriolle A, Camilleri E, Cheneau E, Cabassome E, Dignat-George F, Camoin-Jau L, Paganelli F. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol. 2011;58:467-473. doi: 10.1016/j.jacc.2011.04.017.
6. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097-1105. doi: 10.1001/jama.2011.290.
7. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59:2159-2164. doi: 10.1016/j.jacc.2012.02.026.
8. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100-2109. doi: 10.1056/NEJMoa1209979.
9. Chin CT, Wang TY, Anstrom KJ, Zhu B, Maa JF, Messenger JC, Ryan KA, Davidson-Ray L, Zettler M, Effron MB, Mark DB, Peterson ED. Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. Am Heart J. 2011;162:844-851. doi: 10.1016/j.ahj.2011.08.021.
10. An international randomized trial comparing four thrombolytic strategies for acute MI. The GUSTO investigators. N Engl J Med. 1993;329:673-682.
11. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747. doi: 10.1161/CIRCULATIONAHA.110.009449.
12. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Büttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564. doi: 10.1161/01.CIR.0000160869.75810.98.
13. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246-251. doi: 10.1016/j. jacc.2004.09.067.
14. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614-623. doi: 10.1016/S0140-6736(13)61170-8.
15. Ahn SG, Lee SH, Yoon JH, Kim WT, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Choe KH. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv. 2012;5:259-267. doi: 10.1016/j. jcin.2011.12.009.
16. Park DW, Ahn JM, Song HG, Lee JY, Kim WJ, Kang SJ, Yun SC, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2013;165:34-42.e1. doi: 10.1016/j. ahj.2012.10.013.
17. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-e651. doi: 10.1161/CIR.0b013e31823ba622.
18. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:645-681. doi: 10.1016/j.jacc.2012.06.004.
19. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054. doi: 10.1093/eurheartj/ehr236.
20. Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K; Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209-215. doi: 10.1093/eurheartj/eht375.
21. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404-1411. doi: 10.1016/j. jacc.2007.12.044.
22. Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, Barragan P, Dignat-George F, Paganelli F. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol. 2009;103:5-10. doi: 10.1016/j. amjcard.2008.08.048.
23. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306:1215-1223. doi: 10.1001/jama.2011.1332.
24. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124:1132-1137. doi: 10.1161/CIRCULATIONAHA.111.029165.
25. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601-1606. doi: 10.1016/j.jacc.2013.01.024.
26. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57:2474-2483. doi: 10.1016/j.jacc.2010.12.047.
27. Angiolillo DJ. Applying platelet function testing in clinical practice: what are the unmet needs? JAMA. 2011;306:1260-1261. doi: 10.1001/jama.2011.1349.
28. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Evidence that preexistent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007;5:75-81. doi: 10.1111/j.1538-7836.2006.02234.x.
29. Bagai A, Peterson ED, Honeycutt EM, Effron MB, Cohen DH, Goodman SG, Anstrom K, Gupta A, Messenger JC, Wang TY. In hospital switching of ADPris in MI patients treated with PCI: insights from the TRANSLATEACS study. Circulation. 2012;126:A15573.
30. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. doi: 10.1056/NEJMoa0706482.
31. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.